Immuron has announced the appointment of Dr Jerry Kanellos as the company's new Chief Operating and Scientific Officer.
Dr Kanellos has over two decades experience in the pharmaceutical and biotechnology industry, having held leadership roles in business development, project management, intellectual property portfolio management, R&D and senior management.
Dr Kanellos spent five years with TransBio Limited as Chief Operating Officer, where he was responsible for the strategic identification, development and maintenance of commercial partnerships globally, along with development, management and maintenance responsibility for the intellectual property portfolio, R&D and technology transfer.
He previously spent five years as a consultant to the biotechnology industry and ten years in R&D at CSL, where he gained considerable experience in the drug development process.
According to Immuron Chairman, Dr Roger Aston, "Dr Kanello's past experience in vaccine development, clinical trial management, and regulatory affairs will provide great support to our manufacturing capability and will complement the efforts of Immuron's VP of Innovation Dan Peres".